Brief: NKGen Biotech Secures Additional Financing of $5 Mln To Continue Advancing Its Clinical Programs
11/04/2024 15:33
April 11 (Reuters) - Nkgen Biotech Inc NKGN.O :
* NKGEN BIOTECH SECURES ADDITIONAL FINANCING OF $5 MILLION
TO
CONTINUE ADVANCING ITS CLINICAL PROGRAMS
* NKGEN BIOTECH INC: COMPANY'S NEURODEGENERATIVE CLINICAL
PROGRAM
REMAINS ON TRACK
Source text for Eikon: ID:nGNXdxx0s
Further company coverage: NKGN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nkgen Biotech
See all newsBrief: Nkgen Biotech Expands Clinical Trial Site Network For Alzheimer’S Disease Program Across US
Brief: NKgen Biotech And Hekabio Enter Into Strategic Partnership
Brief: Nkgen Biotech Announces International And U.S. Expansion Of Phase 1/2A Troculeucel Alzheimer’S Trial
Brief: Nkgen Biotech Announces Administration Of First Dose Of Troculeucel To Stroke Patient Under FDA-Cleared Compassionate Use Program
Brief: NKGen Biotech Announces Administration Of First Dose Of Troculeucel To Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program